AU2021346954A1 - Novel aminopyridines and their use in treating cancer - Google Patents

Novel aminopyridines and their use in treating cancer Download PDF

Info

Publication number
AU2021346954A1
AU2021346954A1 AU2021346954A AU2021346954A AU2021346954A1 AU 2021346954 A1 AU2021346954 A1 AU 2021346954A1 AU 2021346954 A AU2021346954 A AU 2021346954A AU 2021346954 A AU2021346954 A AU 2021346954A AU 2021346954 A1 AU2021346954 A1 AU 2021346954A1
Authority
AU
Australia
Prior art keywords
nhr
alkyl
nhc
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021346954A
Other languages
English (en)
Other versions
AU2021346954A9 (en
Inventor
Benjamin D DICKSON
Michael Patrick Hay
Cho Rong Hong
Stephen Michael Frazer Jamieson
Lydia Pieng Ping LIEW
William Robert Wilson
Way Wua WONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of AU2021346954A1 publication Critical patent/AU2021346954A1/en
Publication of AU2021346954A9 publication Critical patent/AU2021346954A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2021346954A 2020-09-24 2021-09-24 Novel aminopyridines and their use in treating cancer Pending AU2021346954A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ768245 2020-09-24
NZ76824520 2020-09-24
PCT/IB2021/058707 WO2022064430A1 (en) 2020-09-24 2021-09-24 Novel aminopyridines and their use in treating cancer

Publications (2)

Publication Number Publication Date
AU2021346954A1 true AU2021346954A1 (en) 2023-05-25
AU2021346954A9 AU2021346954A9 (en) 2024-02-08

Family

ID=80844550

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021346954A Pending AU2021346954A1 (en) 2020-09-24 2021-09-24 Novel aminopyridines and their use in treating cancer

Country Status (7)

Country Link
US (1) US20230365559A1 (https=)
EP (1) EP4217357A4 (https=)
JP (1) JP7839786B2 (https=)
CN (1) CN116669725A (https=)
AU (1) AU2021346954A1 (https=)
CA (1) CA3192868A1 (https=)
WO (1) WO2022064430A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
JP2026509874A (ja) * 2023-03-13 2026-03-25 インサイト・コーポレイション キナーゼ阻害剤としての二環式尿素

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
CA2902858A1 (en) * 2013-02-28 2014-09-04 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
ME03336B (me) * 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
JP6883653B2 (ja) 2016-12-20 2021-06-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用
JP7202315B2 (ja) * 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
GB201819126D0 (en) * 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
WO2020140054A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors

Also Published As

Publication number Publication date
JP2023542548A (ja) 2023-10-10
WO2022064430A1 (en) 2022-03-31
EP4217357A4 (en) 2024-11-06
EP4217357A1 (en) 2023-08-02
AU2021346954A9 (en) 2024-02-08
JP7839786B2 (ja) 2026-04-02
CN116669725A (zh) 2023-08-29
CA3192868A1 (en) 2022-03-31
US20230365559A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
US11987584B2 (en) Heterobicyclic amides as inhibitors of CD38
TWI393566B (zh) 作為週期素依賴性激酶之新穎吡唑并嘧啶
CN109906227B (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
RU2470934C1 (ru) Новое трициклическое производное или его фармацевтически приемлемые соли, способ их получения и содержащая их фармацевтическая композиция
KR100697746B1 (ko) 키나제 저해제로서의 디아제피노인돌 유도체
US20240368169A1 (en) Substituted tricyclic compounds as parp inhibitors and use thereof
JP2019508467A (ja) 癌治療用の２−シアノイソインドリン誘導体
KR20190092542A (ko) Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물 및 이의 사용 방법
KR20110039383A (ko) ｃＭＥＴ 억제제
AU2021346954A1 (en) Novel aminopyridines and their use in treating cancer
JP7777596B2 (ja) Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
CN106488918B (zh) 三唑并嘧啶酮或三唑并吡啶酮衍生物及其用途
CN114206853A (zh) 用于治疗的parp14的靶向蛋白质降解
US20190374526A1 (en) Substituted Heterocyclic Compounds as Inhibitors of PRDM9
CN117425648A (zh) 作为parp7抑制剂的化合物
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
AU2020299659A1 (en) Compound for inhibiting EGFR kinase and preparation method and use thereof
HK40129150A (en) Azaquinolines as inhibitors of cd38
JP2025525031A (ja) 治療に使用するためのｐａｒｐ１４の標的化タンパク質分解
EP2017277A1 (en) Thiophene-imidazopyridines
EA048196B1 (ru) Гетеробициклические амиды как ингибиторы cd38
HK1210777A1 (en) Quinazolinone derivatives as parp inhibitors
HK1164292B (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
SREP Specification republished